{"title":"Emerging precision therapies for gastric cancer","authors":"E. Cartwright, A. Athauda, I. Chau","doi":"10.1080/23808993.2020.1760089","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction Gastric cancer (GC) is a leading cause of cancer-related death and a significant global health burden. Chemotherapy remains the mainstay of treatment in advanced disease and only trastuzumab in combination with upfront fluoropyrimidine/platinum chemotherapy for human epidermal growth factor receptor 2 (HER2) positive disease and ramucirumab together with paclitaxel in the second line have demonstrated a significant survival benefit over chemotherapy alone. Despite the focus on a molecularly targeted approach, treatment gains have been modest and GC remains an area of great unmet need. Areas covered In this review, we provide an overview of the continuum of care in GC, the molecular characterization of GC, targeted therapies currently under investigation and the role of immunotherapy. Expert commentary Gastric cancer is a heterogeneous disease. A targeted approach based upon molecular phenotype holds promise for improving outcomes.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"299 - 311"},"PeriodicalIF":1.0000,"publicationDate":"2020-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1760089","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2020.1760089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1
Abstract
ABSTRACT Introduction Gastric cancer (GC) is a leading cause of cancer-related death and a significant global health burden. Chemotherapy remains the mainstay of treatment in advanced disease and only trastuzumab in combination with upfront fluoropyrimidine/platinum chemotherapy for human epidermal growth factor receptor 2 (HER2) positive disease and ramucirumab together with paclitaxel in the second line have demonstrated a significant survival benefit over chemotherapy alone. Despite the focus on a molecularly targeted approach, treatment gains have been modest and GC remains an area of great unmet need. Areas covered In this review, we provide an overview of the continuum of care in GC, the molecular characterization of GC, targeted therapies currently under investigation and the role of immunotherapy. Expert commentary Gastric cancer is a heterogeneous disease. A targeted approach based upon molecular phenotype holds promise for improving outcomes.
期刊介绍：
Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
